NCT01788553

Brief Summary

The aim of the study is to assess the remission rates in patients treated for generalized anxiety disorder in primary and specialized care. Factors that may influence remission such as disease history and severity of the anxiety disorder, the type of treatment, the presence of co-morbid depression or anxiety disorder as well as socio-demographic factors will also be evaluated. The study will also assess patient functioning and compare functioning in patients who do and do not achieve remission.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
750

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Mar 2006

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2006

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2006

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2007

Completed
2.4 years until next milestone

First Submitted

Initial submission to the registry

July 6, 2009

Completed
3.6 years until next milestone

First Posted

Study publicly available on registry

February 11, 2013

Completed
Last Updated

May 3, 2022

Status Verified

April 1, 2022

Enrollment Period

Same day

First QC Date

July 6, 2009

Last Update Submit

April 28, 2022

Conditions

Anxiety Disorders

Keywords

remissiongeneralized anxiety disorder

Outcome Measures

Primary Outcomes (1)

  • remission of generalized anxiety disorder

    5 months

Secondary Outcomes (1)

  • determine the effect of disease and treatment factors on remission rates

    5 months

Study Arms (1)

patients with generalized anxiety disorder

Other: remission prevalence of generalized anxiety disorder

Interventions

remission prevalence of generalized anxiety disorderOTHER
patients with generalized anxiety disorder

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients treated with generalized anxiety disorder in primary and specialized care in Belgium.

You may qualify if:

  • To be eligible the patient must meet all of the following:
  • Being treated for generalized anxiety disorder for approximately 3 months and not more than 12 months
  • Be at least 18 years of age;
  • Written informed consent
  • Out-patient

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Pfizer Inc.

Brussels, Belgium

Location

MeSH Terms

Conditions

Anxiety DisordersGeneralized Anxiety Disorder

Condition Hierarchy (Ancestors)

Mental Disorders

Study Officials

  • Medical Monitor

    Wyeth is now a wholly owned subsidiary of Pfizer

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 6, 2009

First Posted

February 11, 2013

Study Start

March 1, 2006

Primary Completion

March 1, 2006

Study Completion

March 1, 2007

Last Updated

May 3, 2022

Record last verified: 2022-04

Locations

BE(1)